• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Calliditas Therapeutics AB

    9/13/24 4:15:33 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALT alert in real time by email
    POS AM 1 tm2423885d1_posam.htm POS AM

     

    As filed with the Securities and Exchange Commission on September 13, 2024

    Registration No. 333-265881

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

      

    Post-Effective Amendment No. 1 to

     

    FORM F-3

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

     

    Calliditas Therapeutics AB

    (Exact name of Registrant as specified in its charter)

     

     

     

    Sweden   2834   N/A
    (State or other jurisdiction of
    incorporation or organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification No.)

     

    Kungsbron 1, D5
    SE-111 22
    Stockholm, Sweden
    Tel: +46 (0) 8 411 3005

    (Address, including zip code, and telephone number, including
    area code, of registrant’s principal executive offices)

     

     

     

    Calliditas NA Enterprises Inc.
    330 Madison Avenue, Suite 2310
    New York, New York 10017
    (332) 910-9193

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Joshua A. Kaufman

    Sanjay M. Shirodkar
    DLA Piper LLP (US)
    1251 Avenue of the Americas
    New York, NY 10020
    (212) 335-4500

    Dain Hard Nevonen
    Linnéa Sellstrom
    Advokatfirman Vinge KB
    Smålandsgatan 20, Box 1703
    SE-111 87
    Stockholm, Sweden
    +46(0) 10 614 30 00

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. x

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ¨

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨    Accelerated filer x    Non-accelerated filer ¨    Smaller reporting company ¨    Emerging growth company ¨

     

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

    † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Post-Effective Amendment No. 1 relates to the Registration Statement on Form F-3 (File No. 333-265881) filed by Calliditas Therapeutics AB, a Swedish company with limited liability (the “Company”), which was originally declared effective by the Securities and Exchange Commission (the “SEC”) on July 8, 2022 (such registration statement, the “Registration Statement”). The Registration Statement registered the offer and sale of up to $200,000,000 of the Company’s common shares, including common shares represented by American Depositary Shares, as well as debt securities, warrants and units.

     

    In accordance with an undertaking made by the Company in the Registration Statement to remove from registration by means of a post-effective amendment any securities which remain unsold at the termination of the offering, this Post-Effective Amendment No. 1 is being filed to remove from registration all securities registered but not sold under the Registration Statement. As a result of this deregistration, no securities remain registered for sale pursuant to the Registration Statement.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that is has meet all requirements for filing of this Amendment No. 1 on Form F-3 and has duly caused this Registration Statement amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Stockholm, Sweden, on September 13, 2024.

     

      CALLIDITAS THERAPEUTICS AB
       
      By: /s/ Renée Aguiar-Lucander
        Renée Aguiar-Lucander
    Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Renée Aguiar-Lucander   Chief Executive Officer   September 13, 2024
    Renée Aguiar-Lucander   (Principal Executive Officer)    
             
    /s/ Fredrik Johansson   Chief Financial Officer   September 13, 2024
    Fredrik Johansson   (Principal Financial Officer and Principal Accounting Officer)    
             
    *   Chairman of the Board of Directors   September 13, 2024
    Elmar Schnee        
             
    *   Director   September 13, 2024
    Elisabeth Björk        
             
    *   Director   September 13, 2024
    Hilde Furberg        
             
    /s/ Fred Driscoll   Director   September 13, 2024
    Fred Driscoll        
             
    *   Director   September 13, 2024
    Diane Parks        
             
    *   Director   September 13, 2024
    Henrik Stenqvist        

      

    *By: /s/ Renée Aguiar-Lucander  
      Renée Aguiar-Lucander  
      Attorney-in-Fact  

     

     

    Get the next $CALT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALT

    DatePrice TargetRatingAnalyst
    6/20/2023$60.00Buy
    H.C. Wainwright
    3/1/2023$18.00Neutral
    Guggenheim
    12/20/2021$52.00 → $62.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Calliditas Therapeutics AB with a new price target

      H.C. Wainwright initiated coverage of Calliditas Therapeutics AB with a rating of Buy and set a new price target of $60.00

      6/20/23 7:20:21 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Calliditas Therapeutics AB with a new price target

      Guggenheim initiated coverage of Calliditas Therapeutics AB with a rating of Neutral and set a new price target of $18.00

      3/1/23 6:14:34 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Calliditas Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Calliditas Therapeutics with a rating of Buy and set a new price target of $62.00 from $52.00 previously

      12/20/21 6:22:01 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

      STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: [email protected] The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET. About Calliditas Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan in

      9/16/24 9:46:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

      STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the extraordinary general meeting on Monday 30 September 2024 at 12:00 p.m. CEST at Advokatfirman Vinge's premises on Smålandsgatan 20, SE-111 46, Stockholm, Sweden. Registration starts at 11:30 a.m. CEST. Background Asahi Kasei Corporation ("Asahi Kasei"), which has announced that the public offer made regarding the company's shares has been accepted to such extent that Asahi Kasei becomes the owner of more than 90 per cent of the shares and votes in the company, has requested the board of dire

      9/3/24 7:13:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

      STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (NASDAQ:CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions. Delisting of Common Shares and Delisting, Deregistration, and Termination of ADS Program In light

      9/3/24 6:31:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Financials

    Live finance-specific insights

    See more
    • Calliditas Interim Report January to June 2024

      STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive prog

      8/13/24 1:22:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invitation to the presentation of Calliditas's interim report January - June 2024

      STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast:  https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024 To participate via conference call please register via this link: https://conference.financialhearings.com/tel

      8/5/24 1:19:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

      STOCKHOLM, June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2023. Allocation of profit or loss                                            

      6/17/24 12:01:00 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

      SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/23/24 7:32:15 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

      SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/17/24 7:55:03 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Calliditas Therapeutics AB

      SC 13G/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/11/24 7:42:16 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Leadership Updates

    Live Leadership Updates

    See more
    • Calliditas Therapeutics appoints Maria Törnsén as President North America

      STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America. Ms Törnsén will be responsible for all US based operations and will report to the CEO. Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics. Prior to joining Sarepta she serv

      1/7/24 11:19:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

      FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

      6/3/22 8:00:00 AM ET
      $CALT
      $CELU
      $CTIC
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

      FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022.       Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (NASDAQ:URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease. She brings over two decades of global finance expertise and has

      3/22/22 8:02:00 AM ET
      $CALT
      $PHAT
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Calliditas Therapeutics AB

      15F-12B - Calliditas Therapeutics AB (0001795579) (Filer)

      9/23/24 4:44:35 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Calliditas Therapeutics AB

      25-NSE - Calliditas Therapeutics AB (0001795579) (Subject)

      9/20/24 4:45:11 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB

      SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/18/24 9:02:28 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

      Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

      12/20/21 3:40:41 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care